This retrospective study is to investigate the safety and efficacy of the stent implanting for treating severe symptomatic atherosclerotic stenosis of the intracranial vertebrobasilar artery (ICVBA). 213 patients who had undergone intervention for severe symptomatic ICVBA stenosis between September 2012 to May 2018 were enrolled into this study. Among the 213 enrolled patients, 210 patients (98.6%) obtained successfully revascularization and 206 patients (96.7%) had good revascularization after stenting. The extent of stenosis before and after intervention was 86.3 ± 6.8% and 9.1 ± 3.7%, respectively. Within 90 days after stenting, 10 patients (4.7%) experienced primary endpoint events, including 4 cases (4.2%) in the intracranial vertebral artery (V4) group and 6 (5.1%) in basilar artery (BA) group. Among them, 2 (2.1%) and 3 cases (2.5%) of ischemic stroke in V4 and BA group, respectively; and 2 (2.1%) and 2 (1.7%) cases of TIA in V4 and BA group, respectively. One (0.8%) case in the BA group dead because of the acute stent occlusion resulted in the top of the basilar syndrome. Six patients (2.8%) experienced adverse events, including 2 (2.1%) and 4 (3.4%) cases of groin hematoma in the V4 and BA group, respectively. No cases of hemorrhagic stroke, stent dislocation and vessel dissection in both groups. Our study showed that a low complication rate and a high and good revascularization rate would be achieved by the treatment of severe symptomatic atherosclerotic stenosis of the ICVBA using the stents.
Introduction
Patients with transient ischemic attack (TIA) or ischemic stroke in the vertebrobasilar territory accounts for approximately 20% of all cases of TIA and ischemic stroke [1, 2] . Studies showed that about a quarter of these patients have atherosclerotic stenosis of at least 50% of the vertebrobasilar artery [3, 4] , which has been shown to be associated with an increased risk of 90-day recurrent vertebrobasilar stroke, particularly in the first few weeks [3, [5] [6] [7] , which is significantly higher when compared to the patients with stenosis of the anterior circulation [3, 6] . Therefore, an aggressive treatment is important for the patients' prognosis. However, the annual stroke rates of rigorous medical treatment for patients with vertebrobasilar stenosis are as high as 10À15% [8, 9] and even up to 33% in the first 3 months post first event [7] . Fortunately, the endovascular therapy has been shown as an important method to prevent stroke and its recurrence ascribed to the severe symptomatic atherosclerotic stenosis of intracranial artery [10] . Because many studies showing better outcomes and safety of patients treated with intracranial stents than that of patients treated with the medical therapy [11] [12] [13] , despite of an opposite result showed by the SAMMPRIS study [14] . Although different results were obtained from these clinical trials, the positive results of some patients received better outcomes from the intracranial stents suggested that a subgroup of patient could indeed benefit more from this treatment than those benefit from the medical therapy.
In this study, we aimed to review the experience in our institution of 213 patients accepting endovascular treatment of severe intracranial vertebrobasilar stenosis. We will share the experiences of patients' selection, perioperative preparation, complication management based on the higher successful recanalization rate and safety and better outcomes of patients with severe symptomatic of intracranial vertebrobasilar atherosclerotic stenosis. 
Materials and methods

General clinical information
The clinical information of 213 consecutive patients with symptomatic stroke or transient ischemic attack (TIA) within 90 days ascribed to the severe atherosclerotic stenosis of intracranial vertebrobasilar artery were collected in the stroke database of the Department of Neurology, Xinqiao Hospital of the Army Medical University (Third Military Medical University) from September 2012 to May 2018. The study was approved by the Medical Ethics Committee of Xinqiao Hospital, the Army Medical University. Written informed consent was obtained from the patients or their authorized family members. The study protocol was performed in accordance with relevant ethical guidelines and regulations for human studies.
Patients' selection criteria
Patients were aged 18-85 years and had a symptomatic intracranial atherosclerotic stenosis (ICAS) of 70% to 99% with a lesion length of 15 mm and target vessel diameter of !2.0 mm in the intracranial vertebral artery (V4) and/or basilar artery (BA). The stenosis of the intracranial vertebrobasilar artery was evaluated on digital subtraction angiography (DSA) based on the warfarin-aspirin symptomatic intracranial disease criteria [15] . The symptoms of TIA or stroke within the past 90 days must be due to the hypoperfusion in the territory of the target lesion measured on computed tomography perfusion (CTP) imaging. All patients received evaluations by experienced experts in neurology and a series of corresponding evaluations were performed to confirm the feasibility of receiving stent implantation therapy.
Patients were excluded if the acute infarcts were occurred within 3 weeks, nonatherosclerotic lesion confirmed by highresolution MRI, embolic or perforator stroke based on MRI or CT, baseline modified Rankin Scale score of >3, or a severe vessel tortuosity. The patients were also excluded including concurrence with intracranial pathology including tumors, aneurysms, or arteriovenous malformation; contraindication to heparin, aspirin, clopidogrel, and anesthetic, metal, or contrast media. In addition, women during gestation or lactation period, patients whose life expectancy of less than 5 years due to other medical conditions and failure to follow up on time were also excluded.
Perioperative management
According to the guidelines of ICSA diagnosis and treatment of China, the DSA or CT angiography (CTA) and CT perfusion (CTP) were arranged to evaluate the ischemic degree of the posterior cerebral artery during the hospitalization in our stroke center. The CTP examination was performed to assess cerebral circulation reserve of all patients before the endovascular therapy. All the patients started receiving aspirin (100 mg/d) and clopidogrel (75 mg/d) daily three to five days before stenting or a loading dose of 300 mg clopidogrel if the procedure was considered urgent. All patients were given a dose of 40 mg enoxaparin every 12 h subcutaneously for 3-5 days after stenting and monitored closely until discharge. They were maintained on aspirin (100 mg/d) and clopidogrel (75 mg/d) for 90 days after stenting. Hyperlipidemia was treated to maintain low-density lipoprotein (LDL) levels at 70 mg/dL (1.81 mmol/L) or a decrease by 50%. Those patients with freshly ischemic lesion and massive cerebral infarction needed medical treatment for at least 3 weeks to 1 month before stenting.
Stenting procedure
The procedures were performed by three experienced neurointerventionists who have more than 100 cases of intracranial stent implantation. After general anesthesia, the patients received 3000 U of low-molecular-weight heparin sodium intravenously for systemic heparinization. Right femoral artery puncture was performed using the Seldinger technique to place a 6F/8F arterial sheath. The guiding catheter was advanced into the cervical vertebral artery as high as the vessel tortuosity allowed. A Gateway balloon was placed across the stenotic segment for balloon dilation. Then, the balloon was removed and the Wingspan or Apollo stent was placed in the lesioned vessel, according to the following criteria: the Wingspan stents were used when the lesions were tortuosity, the length between 10 and 15 mm, and the diameter between 2 and 2.5 mm; the Apollo stents were used when the lesions were straight, the length <10 mm, and the diameter >2.5 mm. After radiographic examination revealed that the degree of stenosis had significantly improved, the stent delivery system was removed. After observation for half an hour, intracranial angiography was repeated. The surgery was completed when no abnormalities were observed.
Primary and secondary outcomes
The primary outcome within 90 days was any stroke (including ischemic or hemorrhagic stroke), TIA, and death after stenting. Ischemic stroke is defined as a new focal neurological deficit of sudden onset, lasting 24 h or longer, unassociated with hemorrhage confirmed by CT or MRI images. Hemorrhagic stroke is defined as a new cerebral hemorrhage, involving parenchymal, subarachnoid, and/or intraventricular hemorrhage, that is associated with a seizure, symptoms or signs lasting at least 24 h. TIA is considered as a transient event of neurological dysfunction caused by focal brain or retinal ischemia that lasts for at least 10 min but restores within 24 h despite diffusion-weighted imaging changes. The secondary outcomes were successful revascularization (residual stenosis <20%), good revascularization (the modified TICI (mTICI) grade !2b) [16] and complications, including symptomatic intracranial hemorrhage (sICH), vessel dissection, subarachnoid hemorrhage within 24 h (18-36 h), stent dislocation, or acute stent occlusion [17] during the procedure and perioperation.
Statistical methods
Descriptive analysis was performed. Categorical data were reported as proportions, continuous data were reported as mean ± SD. All analyses were performed using the SPSS13.0 software (SPSS, Chicago, IL, USA).
Results
Patient characteristics
A total of 213 patients (aged 57.4 ± 11.8 years) from September 2012 to May 2018 were enrolled in this retrospective analysis, including 118 patients (55.4%) only with BA stenosis, and 95 patients (44.6%) only with V4 stenosis. In the BA group, 76 cases used Wingspan stents and 42 cases used Apollo stents. In the V4 group, 49 cases used Wingspan stents and 46 cases used Apollo stents. The baseline characteristics of these patients are presented in Table 1 . 74.2% of all the patients had hypertension. The main qualifying event was stroke in 57.3% of the patients. Hypoperfusion was all confirmed by DSA at the time of stenting. The mean time from the qualifying event to endovascular therapy was 23 days (17 days for TIA and 29 days for stroke). The mean degree of stenosis before intervention was 86.3% (Fig. 1A, B and Fig. 2A, B) , while after intervention it was 9.1% ( Fig. 1C and Fig. 2C ). The CTP showed that the features of cerebral blood flow in the side of ischemic territory were worse than that in the contralateral cerebral tissues (Fig. 1D and Fig. 2D) . Additionally, the mean stenting procedure time was 92.5 min. The median time from stenting to discharge was 6 days (interquartile range, 4-7 days).
Primary and secondary outcomes
The 90-day rate of primary outcome was 4.2% (4/95) and 5.1% (6/118) in patients with V4 and BA stenosis, respectively (Table 2) . Ischemic stroke occurred in 2 patients (2.1%) and TIA in 2 patients (2.1%) with V4 stenosis, and ischemic stroke occurred in 3 patients (2.1%) and TIA in 2 patients (2.1%) with BA stenosis, all these events were related to the target territories because of worse revascularizations (mTICI grades less than 2b; Table 3 ). Besides, 1 death occurred in BA stenosis due to the top of the basilar syndrome caused by acute stent occlusion. No non-territory ischemic stroke or hemorrhagic stroke.
Successful revascularization was 98.9% and 98.3% in patients with V4 and BA stenosis, respectively ( Table 2 ). While good revascularization was 95.8% and 97.5% in patients with V4 and BA stenosis, respectively (Table 2 and 3). The other adverse effects included 2 and 4 patients with groin hematoma in V4 and BA stenosis group, respectively. No stent dislocation, vessel dissection, and acute stent occlusion happened. The 1-and 2-year incidence rates of endpoint events were 5.70% and 10.24%, respectively (Fig. 3) .
Discussion
The aim of this retrospective study was to evaluate the effectiveness and safety of endovascular stenting implanting for patients with ischemic stroke or TIA caused by intracranial vertebrobasilar artery stenosis. In the analysis of endovascular treatment of 213 patients with severe intracranial vertebrobasilar stenosis, the stenting implanting was shown to be safe and effectiveness. The 90-day stroke or mortality rate in our study was 5.2% (11/213), which was significantly less than that of the endovascular treatment of the SAMPPRIS trial (14.7%). Additionally, a successful and good revascularization results were acquired (98.6%, 96.7%). To our knowledge, this study is the largest series to report the stenting implanting for stroke or TIA patients with severe intracranial vertebrobasilar stenosis.
In the previous studies, the rates of stroke recurrence or death (the primary outcome) in symptomatic intracranial vertebrobasilar stenosis were inconsistent, some were higher while some lower. For example, the SAMMPRIS and VISSIT trials have reported a higher primary outcome of 14.7% and 24.1% within 30 days [11, 14] , while most of recent reports showed a lower risk of recurrent stroke or death in the endovascular treatment of intracranial vertebrobasilar artery stenosis [12, 18] . Additionally, a meta-analysis including 23 studies with 592 medical treatment patients and 480 endovascular treatment patients who were subjected symptomatic intracranial vertebrobasilar stenosis showed that the risk of combined stroke recurrence or death was 8.9 per 100 personyears in the endovascular group [19] . In our study, we found that the rates of recurrence stroke or death within 90 days were 4.2% and 5.1% in the V4 and BA, respectively, which was lower than most of the previous reports.
As we previously reported [20] , several factors may have contributed to the high successful revascularization rate and low event rates for the endovascular treatment of intracranial vertebrobasilar artery stenosis in our stroke center. First, all the operators in this study have used these devices to treat intracranial atherosclerosis for at least 100 cases that could ensure the operators' experiences. The second is the appropriate selection of patients by performing CTP and HR-MRI to sufficiently assess the collateral circulation compensation and vascular reserve capacity of brain tissues, which Fig. 3 . Kaplan-Meier survival curve and cumulative rates of endpoint events. The 1-and 2-year incidence rates of endpoint events were 5.70% and 10.24%, respectively.
could exclude out those patients not suitable for the endovascular stenting treatment. The third important factor is rigorous perioperative management. The last but not least is that the choosing of stents should base on the vascular anatomy, lesion morphology, and operators' enriched experience. Although we followed these successful factors, there are still some events were occurred and even 1 patient dead. These were probably explained by the complex brain and hemodynamic situations. There were some insufficient factors in this study. For example, (1) this study was just a retrospective study and without medical treatment comparison; (2) we only analyzed the clinical outcome within 90 days, the long-term outcomes after intracranial vertebrobasilar artery stenting remained unknown. (3) the sample size of this study was not large enough that may result in statistic bias. Although these limitations may compromise the conclusions, which could be effectively confirmed or refuted by future large multi-center, randomized clinical trials.
This retrospective study on the stenting treatment showed that a low complication rate and a high revascularization rate would be achieved in patients with severe intracranial vertebrobasilar artery stenosis.
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